CTLA4 and glioblastoma: Many other ongoing trials are evaluating the combination efficacy of anti-CTLA-4 with anti-PD-1 in treating GBM to improve the potential of these 2 therapeutic strategies that, in monotherapy, maybe have not succeeded in radically changing GBM prognosis.40,41